Cross-Border Healthcare Directive (2011/24)

The Cross-Border Healthcare Directive (Directive 2011/24/EU) establishes the rights of patients to access healthcare in any Member State and to be reimbursed for such care by their home Member State. Adopted after years of contentious case law from the Court of Justice on the intersection of free movement of services and national health systems, the Directive codifies and clarifies the principles developed in the case law, creating a regulatory framework that balances patient mobility with the financial sustainability of national health systems.

Legal Background

The Directive responds to a series of landmark judgments in which the Court of Justice held that healthcare services fell within the scope of Article 56 TFEU on the freedom to provide services. In Kohll (Case C-158/96) and Decker (Case C-120/95), the Court ruled that prior authorisation requirements for cross-border healthcare constituted restrictions on the free movement of goods and services that could not be justified where the care could be provided without delay in the home state.

Vanbraekel (Case C-368/98) established the principle of equivalent reimbursement: where prior authorisation was wrongly refused, the patient was entitled to reimbursement at the rate applicable in the treating Member State. Watts (Case C-372/04) confirmed that the right to receive hospital care abroad without prior authorisation applied where the patient could not obtain treatment in the home state within a medically justifiable time.

The Court’s incremental development of patient mobility rights created legal uncertainty for Member States and health insurers. The Directive was adopted to provide a coherent legislative framework.

Scope and Definitions

The Directive applies to the provision of healthcare — defined as health services provided by health professionals to patients to assess, maintain, or restore their state of health — across Member States (Article 1). The Directive does not affect the organisation and financing of healthcare, which remains a national competence, but ensures that patients who choose to receive care in another Member State are not financially disadvantaged.

The Directive covers all forms of healthcare: consultations, diagnostic tests, treatment, and the dispensing of medicines and medical devices. Long-term care, organ transplantation, and access to and allocation of organs are excluded.

The Right to Reimbursement

Articles 7 through 9 establish the patient’s right to reimbursement. For non-hospital care (Article 7(4)), the patient is entitled to reimbursement up to the level of costs that would have been assumed by the home system, without prior authorisation. The patient pays the full cost upfront and claims reimbursement from their home system upon return.

For hospital care (defined by reference to a list of Annex-identified treatments requiring overnight accommodation or highly specialised care), Member States may require prior authorisation (Article 8). Authorisation may be refused only where: the patient would be exposed to an unacceptable safety risk; the public is exposed to a safety risk; the healthcare is to be provided by a practitioner raising serious compliance concerns; or the patient could receive the same treatment in the home state within a medically justifiable time.

The Court of Justice in Commission v Germany (Case C-156/15) held that Member States must define the scope of hospital care subject to prior authorisation narrowly and may not subject all hospital care to authorisation requirements.

Conditions for Reimbursement

Reimbursement is capped at the cost of the same treatment in the home state (Article 7(4)). The patient bears any additional costs, including the difference between the home and treating state’s tariff rates. Travel and accommodation expenses are generally not reimbursable unless covered by home state rules for domestic care.

Member States may not impose conditions that discriminate against cross-border patients. In Geraets-Smits (Case C-157/99), the Court established that conditions applied to cross-border reimbursement must be objectively justified and proportionate.

Cooperation and Information

Title III of the Directive mandates cooperation between Member States in healthcare delivery. The European Reference Networks (ERNs) established under Article 12 are virtual networks of healthcare providers across the EU that cooperate to improve diagnosis and treatment of rare, complex, and low-prevalence diseases. Over 24 ERNs are operational, covering bone disorders, cancer, cardiovascular diseases, and neurological conditions.

The national contact points established under Article 6 provide information to patients on their rights, procedures for reimbursement, and standards of care. The Commission operates the eHealth Digital Service Infrastructure supporting electronic prescriptions and patient summaries across borders.

Professional Qualifications and Standards

Healthcare professionals must be legally entitled to practise in the treating Member State. The Professional Qualifications Directive (2005/36/EC, as amended) ensures mutual recognition of professional qualifications, enabling doctors, nurses, dentists, midwives, pharmacists, and other regulated health professionals to practise across borders.

The treating Member State’s standards of care apply to treatment provided on its territory. The home Member State may not impose its own clinical standards on treatment provided abroad. Liability for harm caused by cross-border healthcare is governed by the law of the treating state (Article 4(3)).

Impact and Challenges

The Directive has facilitated patient mobility, with estimates suggesting over 200,000 cross-border treatments annually. However, uptake remains limited compared to forecasts, and significant barriers persist: information asymmetry about costs and quality; language barriers; and administrative complexity in reimbursement procedures.

The Commission’s 2022 evaluation identified the need for improved information provision, simplified reimbursement procedures, and enhanced cooperation in health technology assessment. The Health Technology Assessment Regulation (2021/2282), applicable from 2025, provides for joint clinical assessments of health technologies across Member States, reducing duplication and improving evidence-based decision-making.